Lyell Immunopharma - LYEL Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year price objectives for Lyell Immunopharma's stock. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 231.7% from the stock's current price.
View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts.

Lyell Immunopharma's stock was trading at $3.47 at the beginning of 2023. Since then, LYEL stock has decreased by 42.1% and is now trading at $2.01.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our LYEL earnings forecast.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.28. The firm had revenue of $48.39 million for the quarter, compared to analyst estimates of $2.85 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 21.53% and a negative net margin of 216.24%.

ETFs with the largest weight of Lyell Immunopharma (NASDAQ:LYEL) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.47%), Geode Capital Management LLC (1.22%), Charles Schwab Investment Management Inc. (0.45%), Baillie Gifford & Co. (0.31%), Bank of America Corp DE (0.26%) and JPMorgan Chase & Co. (0.23%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends.

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LYEL stock can currently be purchased for approximately $2.01.

Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $501.72 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

The company employs 219 workers across the globe.

The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.